Study Group: Methotrexate Prescribers (US)(?)
Council Members in this Study Group: 37
Request a survey with this Study Group
Leading Experts in this Study Group
Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
Dipti Doshi, MD, is a board certified Rheumatologist at Health Care Partners Medical group, California. Dr. Doshi is also board certified in Internal Medicine. Her special interests are in rheumatoid arthritis, lupus, pain-related to scleroderma, fibromyalgia, and osteoarthritis. Dr. Doshi is interested...
Michele Pauporte, MDDermatologist
Juva Skin and Laser Center
Michele Pauporte, MD, is a Dermatologist at Juva Skin and Laser Center, in New York City. Dr. Pauporte's areas of expertise include cosmetic procedures and the treatment of skin cancers (including Mohs micrographic surgery) and reconstructive surgery. She is also extremely experienced in the use of...
Avram Goldberg, MD,FACRAssistant Professor
Albert Einstein College of Medicine
Avram Goldberg, MD, FACR, is an Attending Physician at North Shore University Hospital and an Assistant Professor at the Albert Einstein College of Medicine, New York. He is part of the Division of Rheumatology where he is responsible for treatment of autoimmune and musculoskeletal diseases including...
Instructor in Medicine
Dana-Farber Cancer Institute, Inc
Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at the Dana Farber Cancer Institute in Boston, MA. His clinical focus is on lymphoma, and he is very involved in Phase II/III clinical trials for new compounds, as well as stem cell transplantation.
Director of Clinical Research - Dermatology
ST LUKE'S-ROOSEVELT HOSPITAL CENTER
Jeffrey Weinberg, MD, is the Director of the Clinical Research Center in the Department of Dermatology at St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center in New York. He is also an Assistant Clinical Professor in the Dermatology Department at Columbia University College of Physicians...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The ECOG study showed increased overall survival in AML patients , aged 16-60 , with higher doses of the anthracyclin Daunorubcin combined with cytarabine. These preliminary studies need to be confirmed and do not extend to AML patients older than 60 where survival is the lowest. High cumulative doses...
The findings that Tamoxifen may enahnce breast cancer growth in cells with decreased expression of acthedrin is ynlikely to have clinical impact for 2 reasons: 1- Most ER postive breast cancer patients by definition have higher expression of cathedrin 2- Tamoxifen is largely replaced by aromatase...
Chronic use of long acting agonists in children is already known to increase hospitlizations from mortality from asthma. This may reflect the severity of asthma in these children and poor access to medical care rather than a direct drug effect. Current Asthma gudelines advocate use of inhaled steroids...
The data about increased risk of thrombosis with Avastin is inflated-to say the least. Avastin"COULD" increase risk of thrombosis by 12 % in a population of cancer patients who are already at increased risk of thrombosis. Moreover , very few clots were fatal. The benefit of increased survival in colorectal...
BMS is forking out a lot of cash ( $ 240 million) for two cancer drugs still in development. BMS may know something I don't!!!
GLG InstituteSM Seminars with this Study Group's Leading Experts(?)
Recent Seminars
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Physician - Division Head
- Director